title: Prospective study of Chlamydia pneumoniae IgG and IgA seropositivity and risk of incident ischemic stroke.
abstract: OBJECTIVE
  Chlamydia pneumoniae infection or exposure to C. pneumoniae was implicated as a risk factor for ischemic stroke. Our aim was to evaluate prospectively the association between the presence of antibodies to C. pneumoniae (IgG and IgA) and the risk of incident ischemic stroke among patients with pre-existing vascular disease.
  
  
  METHODS
  Sera were collected from 3,090 coronary heart disease patients enrolled in a secondary prevention trial. We measured baseline antibodies (IgG and IgA) in the sera of patients who developed subsequent ischemic strokes (cases, n = 134) during follow-up (mean 8.2 years), and in 134 age- and gender-matched pairs without subsequent stroke or myocardial infarction.
  
  
  RESULTS
  The crude relative odds (95%CI) of incident ischemic strokes in seropositive patients at baseline (>1.1 relative value units) were 1.29 (95%CI, 0.69-2.47) for IgG and 1.31 (95% CI, 0.69-2.55) for IgA by matched-pair analyses, and 1.42 (95%CI, 0.69-2.98) for IgG and 1.57 (95%CI, 0.76-3.35) for IgA after adjustments for conventional risk factors and the inflammatory marker, soluble intercellular adhesion molecule-1. We explored the possibility that the risk of ischemic stroke may increase in parallel to increasing antibody titers, but did not demonstrate any significant association.
  
  
  CONCLUSIONS
  Serological evidence for prior infection with C. pneumoniae did not emerge as an independent risk factor for incident ischemic stroke among patients at high risk due to pre-existing vascular disease.
authors.affiliation: Stroke Unit, Department of Neurology, Sheba Medical Center, Tel-Hashomer, Israel. tanne@post.tau.ac.il
authors.forename: David
authors.initials: D
authors.lastname: Tanne
authors.forename: Moti
authors.initials: M
authors.lastname: Haim
authors.forename: Valentina
authors.initials: V
authors.lastname: Boyko
authors.forename: Uri
authors.initials: U
authors.lastname: Goldbourt
authors.forename: Tamar
authors.initials: T
authors.lastname: Reshef
authors.forename: Yehuda
authors.initials: Y
authors.lastname: Adler
authors.forename: Daniel
authors.initials: D
authors.lastname: Brunner
authors.forename: Yoseph A
authors.initials: YA
authors.lastname: Mekori
authors.forename: Solomon
authors.initials: S
authors.lastname: Behar
mesh_terms: D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood*; D001161:Arteriosclerosis / Q000097:blood* / Q000150:complications* / Q000276:immunology; D002545:Brain Ischemia / Q000097:blood* / Q000209:etiology* / Q000276:immunology; D016022:Case-Control Studies; D023521:Chlamydophila Infections / Q000097:blood* / Q000150:complications* / Q000276:immunology; D016993:Chlamydophila pneumoniae / Q000276:immunology* / Q000472:pathogenicity*; D003327:Coronary Disease / Q000097:blood* / Q000150:complications* / Q000276:immunology; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood*; D007074:Immunoglobulin G / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors; D020521:Stroke / Q000097:blood* / Q000209:etiology* / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D007070:Immunoglobulin A; D007074:Immunoglobulin G